Dayvigo

Active Ingredient(s): Lemborexant
FDA Approved: * December 20, 2019
Pharm Company: * EISAI INC
Category: Sleep Aid

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Dayvigo Overview

Lemborexant, sold under the brand name Dayvigo, is a medication for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults.[1][2] Lemborexant was approved in the United States for use by adults with insomnia in December 2019.[3][4][2] Contents 1 Medical uses 2 Pharmacology 2.1 Pharmacodynamics 2.2 Pharmacokinetics 3 History 4 Society and culture 4.1 Generi...

Read more Dayvigo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lemborexant

Recent Dayvigo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Dayvigo: (2 results)

Sorted by National Drug Code

• 62856-405 Dayvigo 5 mg Oral Tablet, Film Coated by Eisai Inc.
• 62856-410 Dayvigo 10 mg Oral Tablet, Film Coated by Eisai Inc.

Other drugs which contain Lemborexant or a similar ingredient: (1 result)

• LEMBOREXANT